Our top pick for
Building a portfolio

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Evelo Biosciences, Inc is a biotechnology business based in the US. Evelo Biosciences shares (EVLO) are listed on the NASDAQ and all prices are listed in US Dollars. Evelo Biosciences employs 90 staff and has a market cap (total outstanding shares value) of USD$534.9 million.
Our top pick for
Building a portfolio
Our top pick for
Beginners
Our top pick for
Active traders
52-week range | USD$3.55 - USD$19.928 |
---|---|
50-day moving average | USD$12.1294 |
200-day moving average | USD$9.6183 |
Wall St. target price | USD$20.2 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | USD$-2.27 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Gross profit TTM | USD$0 |
---|---|
Return on assets TTM | -63.26% |
Return on equity TTM | -206.58% |
Profit margin | 0% |
Book value | $0.642 |
Market capitalisation | USD$534.9 million |
TTM: trailing 12 months
There are currently 2.9 million Evelo Biosciences shares held short by investors – that's known as Evelo Biosciences's "short interest". This figure is 25.7% up from 2.3 million last month.
There are a few different ways that this level of interest in shorting Evelo Biosciences shares can be evaluated.
Evelo Biosciences's "short interest ratio" (SIR) is the quantity of Evelo Biosciences shares currently shorted divided by the average quantity of Evelo Biosciences shares traded daily (recently around 233612.88782816). Evelo Biosciences's SIR currently stands at 12.57. In other words for every 100,000 Evelo Biosciences shares traded daily on the market, roughly 12570 shares are currently held short.
However Evelo Biosciences's short interest can also be evaluated against the total number of Evelo Biosciences shares, or, against the total number of tradable Evelo Biosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Evelo Biosciences's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Evelo Biosciences shares in existence, roughly 60 shares are currently held short) or 0.0928% of the tradable shares (for every 100,000 tradable Evelo Biosciences shares, roughly 93 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Evelo Biosciences.
Find out more about how you can short Evelo Biosciences stock.
We're not expecting Evelo Biosciences to pay a dividend over the next 12 months.
Over the last 12 months, Evelo Biosciences's shares have ranged in value from as little as $3.55 up to $19.928. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Evelo Biosciences's is 1.2498. This would suggest that Evelo Biosciences's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in clinical development trial for the treatment of psoriasis and atopic dermatitis, as well as for the hyperinflammatory response associated with COVID-19. The company also engages in developing EDP1867, an inactivated investigational oral biologic for the treatment of inflammatory diseases; EDP2939, an extracellular vesicle investigational oral biologic for the treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Steps to owning and managing SGLB, with 24-hour and historical pricing before you buy.
Steps to owning and managing SSD, with 24-hour and historical pricing before you buy.
Steps to owning and managing SQNS, with 24-hour and historical pricing before you buy.
Steps to owning and managing SFL, with 24-hour and historical pricing before you buy.
Steps to owning and managing AIHS, with 24-hour and historical pricing before you buy.
Steps to owning and managing ST, with 24-hour and historical pricing before you buy.
Steps to owning and managing SLCT, with 24-hour and historical pricing before you buy.
Steps to owning and managing EYES, with 24-hour and historical pricing before you buy.
Steps to owning and managing SBSW, with 24-hour and historical pricing before you buy.
Steps to owning and managing SHG, with 24-hour and historical pricing before you buy.